Cassava Sciences | PTIE - Gross Profit On Sales


Cassava Sciences reported $-3.96M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Abbott USD 6.65B 787M Jun/2026
Amgen USD 5.87B 1.02B Mar/2026
Biogen USD 2.12B 307M Jun/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cassava Sciences USD -3.96M 1.16M Sep/2025
Eisai JPY 183.24B 29.83B Jun/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
Geron USD 50.14M 3.44M Mar/2026
J&J USD 18.55B 1.31B Jun/2026
Merck USD 12.09B 1.24B Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Novavax USD 125.04M 76.09M Dec/2025
Pfizer USD -248M 11.29B Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026